These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9207341)

  • 41. Mutation causes sensitivity.
    AIDS Patient Care STDS; 2000 Jul; 14(7):395. PubMed ID: 10935056
    [No Abstract]   [Full Text] [Related]  

  • 42. Antiviral treatment of HIV infection.
    Thomas MG; Ellis-Pegler RB
    N Z Med J; 1998 Sep; 111(1074):353-4. PubMed ID: 11039818
    [No Abstract]   [Full Text] [Related]  

  • 43. Rescue regimens: the value of PI boosting.
    Segal-Maurer S; Schütz M
    Posit Aware; 2001; 12(6):35-7. PubMed ID: 11785478
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?
    Aizawa S; Gatanaga H; Ida S; Sakai A; Tanaka M; Takahashi Y; Hirabayashi Y; Oka S
    AIDS; 1999 Jul; 13(10):1278-9. PubMed ID: 10416536
    [No Abstract]   [Full Text] [Related]  

  • 45. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 46. Higher antiviral activity of antiretroviral regimens including protease inhibitors.
    de Mendoza C; Soriano V; Rodríguez-Rosado R; González-Lahoz J
    AIDS; 1999 May; 13(8):998-9. PubMed ID: 10371186
    [No Abstract]   [Full Text] [Related]  

  • 47. What's new in HIV.
    Morris-Jones S; Nelson MR
    J Infect; 1999 Mar; 38(2):i-ii. PubMed ID: 10342641
    [No Abstract]   [Full Text] [Related]  

  • 48. Drug resistance and treatment of experienced patients.
    Gallant JE
    Hopkins HIV Rep; 2003 Mar; 15(2):8-9. PubMed ID: 12739503
    [No Abstract]   [Full Text] [Related]  

  • 49. Safe and effective use of combination antiretroviral treatment.
    Colebunders R; Clumeck N; Florence E; Vandercam B; Van Wanzeele F; Van Wijngaerden E; Lacor P; Demonty J; De Wit S
    Acta Clin Belg; 1999 Apr; 54(2):55-60. PubMed ID: 10394641
    [No Abstract]   [Full Text] [Related]  

  • 50. Adherence to prescribed HIV-1 protease inhibitors in the home setting.
    Ungvarski P
    J Assoc Nurses AIDS Care; 1997; 8 Suppl():37-45. PubMed ID: 9356961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
    Lascar M; Cartledge JD
    J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
    [No Abstract]   [Full Text] [Related]  

  • 52. Saquinavir: an HIV proteinase inhibitor.
    Bragman K
    Adv Exp Med Biol; 1996; 394():305-17. PubMed ID: 8815695
    [No Abstract]   [Full Text] [Related]  

  • 53. [Position of darunavir in antiretroviral therapy].
    Clotet B
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():61-2. PubMed ID: 19195461
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeting HIV: antiretroviral therapy and development of drug resistance.
    Menéndez-Arias L
    Trends Pharmacol Sci; 2002 Aug; 23(8):381-8. PubMed ID: 12377580
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination therapy in the management of HIV infection.
    Vella S; Franca Pirillo M
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():23-6. PubMed ID: 9003571
    [No Abstract]   [Full Text] [Related]  

  • 56. HIV resistance: the new enemy.
    Colvin R
    Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ABT-378: Abbott "second generation" protease inhibitor.
    James JS
    AIDS Treat News; 1997 Feb; (No 265):6. PubMed ID: 11364243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amprenavir may be less cross-resistant with other PIs.
    Murphy MJ
    HIV Clin; 1999; 11(5):1, 7. PubMed ID: 11810849
    [No Abstract]   [Full Text] [Related]  

  • 59. San Francisco General Hospital: studies for patients beginning antiretroviral treatment.
    AIDS Treat News; 1999 Aug; (No 325):7-8. PubMed ID: 11366576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 2000 Mar; 14(5):626-8. PubMed ID: 10780732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.